Eli Lilly and Company (NYSE:LLY – Get Free Report) shares were up 2.4% during mid-day trading on Tuesday after Guggenheim raised their price target on the stock from $855.00 to $884.00. Guggenheim currently has a buy rating on the stock. Eli Lilly and Company traded as high as $796.80 and last traded at $793.65. Approximately 870,083 shares changed hands during trading, a decline of 71% from the average daily volume of 2,998,192 shares. The stock had previously closed at $775.26.
Other analysts have also recently issued reports about the company. Barclays lifted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Argus lifted their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $860.05.
Get Our Latest Stock Report on Eli Lilly and Company
Insider Buying and Selling at Eli Lilly and Company
Institutional Investors Weigh In On Eli Lilly and Company
Large investors have recently modified their holdings of the company. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $26,000. Tidemark LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $32,000. Finally, LGT Financial Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $36,000. 82.53% of the stock is owned by institutional investors and hedge funds.
Eli Lilly and Company Stock Performance
The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a 50 day moving average of $869.05 and a 200 day moving average of $792.14. The stock has a market capitalization of $733.85 billion, a P/E ratio of 113.72, a P/E/G ratio of 1.81 and a beta of 0.41.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- What Are Bonds? A High-Level Overview
- Why Are These Companies Considered Blue Chips?
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- 5 discounted opportunities for dividend growth investors
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.